Shikonin as a therapeutic agent in renal cell carcinoma: insights from TEK-related causal association with glaucoma
These findings support a role for glaucoma-associated genes in RCC development and progression, highlighting shikonin as a promising therapeutic agent targeting this molecular axis.
Authors
- Xiangzhi Li (ORCID: https://orcid.org/0000-0002-7117-4513)
- Jiasheng Bian
- Ruyue Jia
- Benkui Zou
- Yiran Liang (ORCID: https://orcid.org/0000-0002-2404-0408)
- Renbo Guo
- Tao Chen (ORCID: https://orcid.org/0000-0001-9148-7704)
- Chao Zhang (ORCID: https://orcid.org/0009-0008-2674-344X)
Institutions
- Shandong University (CN)
- Shandong Tumor Hospital (CN)
- Qilu Hospital of Shandong University (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-07-30
- DOI
- https://doi.org/10.3389/fphar.2025.1580704
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province